Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values

Levey, Andrew S.; Coresh, Josef; Greene, Tom; Marsh, James E.; Stevens, Lesley A.; Kusek, John W.; Lente, F Van

doi:10.1373/clinchem.2006.077180

Cited by 1,607 publications

(1,222 citation statements)

References 32 publications

Supporting

Mentioning

1,178

Contrasting

Unclassified

Order By: Relevance

“…The calibration matter for creatinine is especially relevant because creatinine is more and more automatically used by laboratories to estimate GFR, notably with the Modification of the Diet in Renal Disease (MDRD) study equations [7,[13][14][15][16]. The impact of the calibration on the MDRD results is far from negligible, especially in the high GFR range [7,9,[17][18][19].…”

Section: Discussionmentioning

confidence: 99%

“…The impact of the calibration on the MDRD results is far from negligible, especially in the high GFR range [7,9,[17][18][19]. The MDRD study equation has even been modified to be useful with IDMS traceable creatinine [13,15]. The need for a traceable, reproducible, method for sCr measurement could be further enhanced using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula taking into account low creatinine value (lower than 62 μmol/L for women) [20].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A multicentric evaluation of IDMS-traceable creatinine enzymatic assays

Piéroni

Delanaye

Boutten³

et al. 2011

Clinica Chimica Acta

104

View full text Add to dashboard Cite

Chronic kidney disease definition is based on glomerular filtration rate (GFR) estimations which are derived from creatinine-based equations. The accuracy of GFR estimation is thus largely dependent of those of serum creatinine assays. International recommendations highlight the need for traceable creatinine assays. The French Society of Clinical Biochemistry conducted a study for measuring accuracy of creatinine enzymatic methods. This evaluation involved 25 clinical laboratories. Creatinine was measured in serum pools ranging from 35.9 ± 0.9 μmol/L to 174.5 ± 3.1 μmol/L (IDMS determination) using 12 creatinine enzymatic methods. For all creatinine values greater than 74.4 ± 1.4 μmol/L, the bias and imprecision did not exceed 5% and 5.9%, respectively. For the lowest value (35.9 ± 0.9 μmol/L), the bias ranged from −1.8 to 9.9% (with one exception). At this level, the imprecision ranged from 1.9 to 7.8%. The true performances of the assays (couples of bias and relative standard deviation), were evaluated using Monte-Carlo simulations. Most of the assays fall within the maximum Total Error of 12% at all concentrations. This study demonstrates substantial improvements in the calibration, traceability and precision of the enzymatic methods, reaching the NKDEP recommendations. Moreover, most of these assays allowed accurate creatinine measurements for creatinine levels lower than 40 μmol/L.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A multicentric evaluation of IDMS-traceable creatinine enzymatic assays

Piéroni

Delanaye

Boutten³

et al. 2011

Clinica Chimica Acta

104

View full text Add to dashboard Cite

show abstract

“…The inclusion criteria were (1) signed informed consent; (2) age ≥18 years, (3) chronic congestive HF, (4) left ventricular ejection fraction ≤40% measured within 2 days before the study, (5) serum NT‐pro‐BNP (N‐terminal probrain natriuretic peptide) ≥500 ng/L measured within 2 days before the study, and (6) GFR estimated (Modification of Diet in Renal Disease)15 or measured ( 51 Cr‐EDTA [chromium ethylene diamine tetraacetic acid]) between 30 and 80 mL/min. The exclusion criteria were (1) untreated acute HF, (2) systolic blood pressure <100 mm Hg, (3) heart rate >100 beats/min, (4) Canadian Cardiovascular Society class III angina pectoris or higher, (5) aortic stenosis, (6) hypertrophic cardiomyopathy, (7) restrictive cardiomyopathy, (8) presence of kidney disease diagnosed before HF, (9) administration of radiographic contrast within the previous week, (10) radiographic contrast allergy, and (11) the opinion of the investigator that the prospective study participant had a clinically significant disease that could be adversely affected by study participation.…”

Section: Methodsmentioning

confidence: 99%

Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial

Lannemyr

Ricksten

Rundqvist

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundThe management of the cardiorenal syndrome in advanced heart failure is challenging, and the role of inotropic drugs has not been fully defined. Our aim was to compare the renal effects of levosimendan versus dobutamine in patients with heart failure and renal impairment.Methods and ResultsIn a randomized double‐blind study, we assigned patients with chronic heart failure (left ventricular ejection fraction <40%) and impaired renal function (glomerular filtration rate <80 mL/min per 1.73 m2) to receive either levosimendan (loading dose 12 μg/kg+0.1 μg/kg per minute) or dobutamine (7.5 μg/kg per minute) for 75 minutes. A pulmonary artery catheter was used for measurements of systemic hemodynamics, and a renal vein catheter was used to measure renal plasma flow by the infusion clearance technique for PAH (para‐aminohippurate) corrected by renal extraction of PAH. Filtration fraction was measured by renal extraction of chromium ethylenediamine tetraacetic acid. A total of 32 patients completed the study. Following treatment, the levosimendan and dobutamine groups displayed similar increases in renal blood flow (22% and 26%, respectively) with no significant differences between groups. Glomerular filtration rate increased by 22% in the levosimendan group but remained unchanged in the dobutamine group (P=0.012). Filtration fraction was not affected by levosimendan but decreased by 17% with dobutamine (P=0.045).ConclusionsIn patients with chronic heart failure and renal impairment, levosimendan increases glomerular filtration rate to a greater extent than dobutamine and thus may be the preferred inotropic agent for treating patients with the cardiorenal syndrome.Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT02133105.

show abstract

“…Renal function was assessed at screening based on creatinine clearance (CL cr ) as an estimation of the glomerular filtration rate (eGFR), and calculated using the Modified Diet in Renal Disease (MDRD) equation 12. Renal function was classified as normal when CL cr was ≥90 ml min –1 , as mildly impaired when CL cr was ≥60 to 89 ml min –1 and moderately impaired when CL cr ≥30 to 59 ml min –1 .…”

Section: Methodsmentioning

confidence: 99%

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease

Rabinovich‐Guilatt

Siegler

Schultz

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimPridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is currently under development. In steady‐state conditions, pridopidine elimination is mediated primarily through renal excretion. This study evaluated single dose and steady‐state pharmacokinetics (PK) of a daily dose of pridopidine in subjects with mild and moderate renal impairment and matched healthy subjects.MethodsSubjects with mild renal impairment (n = 12), moderate impairment (n = 12), or their matched healthy controls (n = 25) participated in this study. Subjects received a single dose of pridopidine (45 mg) on day 1 and a multiple dose cycle of 45 mg once daily on days 5–18. Blood and urine samples were collected on days 1 and 18 for PK analysis.ResultsMild renal impairment did not affect the PK of pridopidine whilst an increase in exposure was seen in subjects with moderate renal impairment. Subjects with moderate impairment showed reduced plasma clearance (by 44%) and had 68% higher AUC (90% CI 1.22, 2.30) and 26% higher C max (90% CI 1.02, 1.56) values than those with normal renal function at steady‐state. Pridopidine was safe and well tolerated in healthy subjects and in subjects with mild and moderate renal impairment.ConclusionsMild renal impairment has no impact on exposure to pridopidine while moderately impaired renal function resulted in higher pridopidine concentrations.

show abstract

Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values

Cited by 1,607 publications

References 32 publications

A multicentric evaluation of IDMS-traceable creatinine enzymatic assays

A multicentric evaluation of IDMS-traceable creatinine enzymatic assays

Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease

Contact Info

Product

Resources

About